De progressionsfri overlevelsesrater for første skemalagte besøg (uge 8) i gruppen med KRAS- vildtypen var 59, 7% for Vectibix plus BSC og 21, 0% for BSC alene, en difference på 38, 7% (95% CI:
The progression-free survival rates at the first scheduled visit (week 8) in the KRAS wild-type group were 59.7% on Vectibix plus BSC and 21.0% on BSC alone, a difference of 38.7% [95% CI: